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Condensation
This pilot RCT suggests day-case management of severe nausea and vomiting in 
pregnancy is an effective alternative to in-patient management for some women.
Abstract
Objective: To assess the feasibility of implementing a complex intervention involving 
rapid intravenous rehydration and ongoing midwifery support as compared to routine 
in-patient care for women suffering from severe nausea and vomiting in pregnancy, 
(NVP)/hyperemesis gravidarum (HG).
Study Design: 53 pregnant women attending the Maternity Assessment Unit (MAU), 
Newcastle upon Tyne NHS Foundation Trust, Newcastle, UK with moderate-severe 
NVP, (as determined by a Pregnancy Unique Quantification of Emesis and Vomiting 
[PUQE] score ≥nine), consented to participate in this pilot randomised controlled trial 
(RCT). Subsequently 27 were randomised to the intervention group, 26 to the control 
group.
Women in the intervention group received rapid rehydration (three litres Hartman’s 
solution over six hours) and symptom relief on the MAU followed by ongoing 
midwifery telephone support. The control group were admitted to the antenatal ward 
for routine in-patient care.
Quality of life (QoL) determined by SF36.V2 score and PUQE score were measured 
7 days following randomisation. Completion rates, readmission rate, length of 
hospital stay and pregnancy outcomes data were collected.
Results: Groups were comparable at baseline.  Questionnaire two return rate was 
disappointing, only 18 womenin the control group (69%) and 13 women in the 
intervention groups (44%). Nonetheless there were no differences between groups 
on Day 7 in terms of QoL, mean PUQE score, satisfaction with care, obstetric and 
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neonatal outcomes or readmission rates. However, total combined admission time 
was higher in the control group (94 hours versus 27 hours, p=0.001). 
Conclusions: This study suggests that day-case management plus ongoing 
midwifery support may be an effective alternative for treating women with severe 
NVP/HG. A larger trial is needed to determine if this intervention affects women’s 
QoL.
Key words: Nausea and vomiting in pregnancy, Hyperemesis gravidarum, 
outpatient management, quality of life, PUQE score
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Conclusions: This study suggests that day-case management plus ongoing 
midwifery support may be an effective alternative for treating women with severe 
NVP/HG. A larger trial is needed to determine if this intervention affects women’s 
QoL.
Key words: Nausea and vomiting in pregnancy, Hyperemesis gravidarum, 
outpatient management, quality of life, PUQE score
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Introduction
Nausea and vomiting in pregnancy, (NVP), is a frequently occurring but often 
debilitating condition, which affects 50-85% of pregnant women (1). In most cases 
symptoms are mild to moderate and self-limiting. However 0.3-1% of pregnancies 
are affected by hyperemesis gravidarum, (HG), defined as severe intractable 
vomiting, ketosis, fluid and electrolyte disturbances, nutritional deficiencies and 
weight loss, (usually more than 5% of the pre-pregnancy weight) (1). There is no 
clearly defined point at which NVP becomes HG and women are usually categorised 
according to the severity of their symptoms. 
Severe NVP/HG has implications for the health and wellbeing of the mother and 
baby. A recent systematic review reported that women with HG were more likely to 
deliver preterm and to have a baby that was small-for-gestational age, although the 
associations are inconsistent, however there was no evidence of an association with 
congenital anomalies or perinatal death (2, 3). 
Severe NVP also causes emotional and psychological distress and can have a 
profound effect on women’s quality of life (QoL) (4, 5). Recent observational studies 
have reported higher incidences of depression, anxiety and stress in women 
diagnosed with HG which can last throughout pregnancy and into the post-natal 
period (6, 7). As a result women with HG make greater use of health care resources; 
HG accounts for 30% of admissions before 20 weeks gestation (8). 
Management of NVP/HG tends to focus on the alleviation of symptoms and 
prevention of serious morbidity. Historically women have been admitted to hospital 
for intravenous (IV) fluid therapy and antiemetics while less time is spent dealing with 
their psychological, social and emotional needs or providing information and 
guidance about the condition. The result is that women can feel unsupported, 
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dissatisfied with care and experience negative interpersonal interactions with health 
care providers (9). 
The aim of this pilot randomised trial was, therefore, to investigate the feasibility of a 
midwifery led out-patient intervention, consisting of rapid intravenous hydration and 
ongoing support versus standard in-patient management. Secondary outcomes 
included differences in QoL, satisfaction with care, readmission rate and pregnancy 
outcomes.
Methods
All pregnant women less than 20 weeks gestation attending the Maternity 
Assessment Unit, (MAU), at Newcastle upon Tyne Hospitals NHS Foundation Trust 
for the first time with moderate-severe NVP, over a twenty month period 
commencing in January 2004, were considered for inclusion in the study. A formal 
sample size calculation was not performed as this was a pilot feasibility study and 
recruitment continued for as long as was practicable and funds were available. 
To assess the severity of their symptoms, women were asked to complete a 
‘Pregnancy Unique Quantification of Emesis and Vomiting Score’ (PUQE score) (10-
12). The scale quantifies the amount of nausea, vomiting and retching over the 
preceding 12 hours, each on a scale of one to five (i.e. maximum score 15). Women 
scoring nine or higher, (the mid-range point for the moderate category), were 
deemed suitable for inclusion in the study. 
Women were excluded if they had an underlying medical condition such as type 1 
diabetes mellitus, renal or cardiac disease, were aged less than16 years, required an 
interpreter or were planning to have a termination of pregnancy. Ethical approval 
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was granted by the Newcastle and North Tyneside Local Research Ethics 
Committee (reference number: 2003/207, approval date 25th February 2004).
After gaining written informed consent women were randomly allocated to receive 
either standard care (control group) or midwifery-led management on the MAU, 
(intervention group), using a web based system. The computer generated sequence 
was produced by a statistician independent of the study team using a fixed block 
size of six and 1:1 allocation. 
Women allocated to the intervention group remained on the MAU. After routine 
clinical observations (temperature, pulse, blood pressure, weight and urinalysis) an 
intravenous (IV) cannula was sited and bloods taken for urea and electrolytes, liver 
function and full blood count. Cyclizine, 50mg IV, was given followed by three litres 
of compound sodium lactate, (Hartman’s), solution over six hours; the first litre over 
one hour, the second over two hours and the third over three hours. Women were 
then given 50mg of oral thiamine and discharged home with a prescription for oral 
cyclizine, 50mg to be taken three times daily for seven days. They were advised to 
see their General Practitioner, (GP) if they needed additional antiemetics. 
Arrangements were made for the study research midwife to contact all women by 
telephone on day three and day seven after randomisation to offer ongoing support, 
reassurance, advice, identify any problems and encourage compliance with anti-
emetics following a standard proforma.
Women allocated to the control group were admitted to the antenatal ward, an IV 
cannula sited and bloods taken. Intravenous cyclizine was given (50mg IV), IV fluids, 
(one litre of Hartman’s solution eight hourly until rehydrated), and a daily dose of oral 
thiamine (50mg). Temperature, pulse, blood pressure, urinalysis, fluid balance and 
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frequency of vomiting were recorded daily. Oral fluids were gradually introduced, 
followed by a bland light diet.  Women were discharged home when they were 
tolerating diet with a prescription for oral cyclizine (as in the intervention group). All 
participants were given an information sheet about NVP which included simple self-
help measures and advice that could be followed at home. 
Immediately after randomisation women completed Questionnaire One, which 
consisted of basic demographic questions, the SF-36v.2, [www.sf36.org, (13)], (a 
quality of life scale which looks at eight dimensions of physical, emotional and 
mental wellbeing). Women were then given Questionnaire Two which asked them to 
complete a PUQE score at the same time every day for the following six days, a 
further SF-36v.2 score seven days after randomisation together with a short 
satisfaction survey (14). Participants were reminded to complete this questionnaire 
when they received their follow up telephone calls, (intervention group), or whilst 
they were inpatients (control group). A freepost envelope was provided to facilitate 
return of this questionnaire. 
Women re-attending the MAU because of persistent or increasing NVP within seven 
days of randomisation were offered a second cycle of the treatment to which they 
had been allocated. If women re-attended a second time within seven days of 
randomisation they were admitted and received standard care on the antenatal ward.
Data analysis
Analysis was by intention-to-treat using SPSS for Windows, (Statistical Package for 
Social Sciences Version 21). Serial PUQE scores were analysed by calculating the 
area under the curve to generate a single summary statistic for each participant (15); 
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groups were then compared using an independent sample t-test, cross tabulations 
and chi-squared analysis were used to detect differences between groups. Analysis 
of co-variance was used to detect differences between the SF36 mean summary 
scores and the PUQE scores on days one and seven. Customised growth centile 
charts were used to calculate birth centiles (16). Small for gestational age (SGA) was 
defined as a birthweight less than the 10th centile for gestational age, maternal parity 
and sex.
Results
A total of 184 women presented at the MAU during the 20-month recruitment period, 
126 of which were eligible to participate. Of these 50 women were not approached 
by the clinical staff, (either because the women presented at hospital overnight or the 
MAU was exceptionally busy), 23 declined participation and 53 were randomised. A 
Consort diagram is presented in Figure 1.
The baseline characteristics of the women in the trial are shown in Table 1. There 
were no differences between the groups in any of the variables, serum urea and 
electrolyte concentrations were within normal ranges for all women. Of the 27 
women randomised to the intervention, 20 (74%) received the first telephone call on 
day three and 16 (59%) received the second call on day seven; 14 (52%) received 
both telephone calls, with each call lasting between two and 10 minutes. 
Only 69% of participants in the control group and 44% of participants in the 
intervention group completed Questionnaire Two, (p=0.06). There was no statistically 
significant association between completion of questionnaire two and subsequently 
re-attendance with a resumption of symptoms.
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Clinical outcomes are shown in Table 2. All women in the trial received IV cyclizine. 
As expected more women in the intervention group received at least three litres of IV 
fluid during the first 24 hours after randomisation and the length of time in hospital for 
the initial attendance was less.  Twenty five (93%) of the women in the intervention 
group were discharged within 12 hours of attendance compared to one (4%) in the 
control group. 
Re-attendance rate and mean PUQE scores on re-attendance were comparable in 
both groups, (12.7 in the control group versus 11.7 in the intervention group, 
p=0.69). Including re-attendances the total time in hospital (related to NVP) was 
greater in the control group, p<0.001. Delivery and neonatal outcomes were similar 
in the two groups. 
Results from the second questionnaire are shown in Table 3. There were no 
differences between the groups in any of the eight health domains of the SF36 score 
(data not shown), the physical and mental health summary scores or satisfaction 
with care.  
In both groups the PUQE score improved significantly by day two with no change 
thereafter and there was no differences in mean area under the curve between 
groups over the seven days, mean difference -5.9 (95% confidence intervals -17.7, 
5.9). 
Discussion
The inpatient experiences of women who present at hospital with severe NVP are 
often negative (17-19).  The findings from this pilot RCT suggest that midwifery-led 
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day-case management of severe NVP provides an alternative management strategy 
to admission.  Women randomised to day-case management had similar 
improvements in objectively assessed NVP with no decrement in QoL scores or 
satisfaction with care measured seven days after randomisation. 
Overall time in hospital was reduced substantially in the intervention group 
suggesting that day-case management is likely to be cost-effective.  The results also 
suggest that a larger trial is feasible; 70% of eligible women approached agreed to 
be randomised.
The intervention was developed in response to a perceived local and national need 
(20, 21) to try and improve the experience of care and reduce hospital stay for 
women with severe NVP. Anecdotally many women report symptomatic 
improvement after IV hydration. This was apparently confirmed in a subsequent 
observational study of day-case management of HG involving rehydration with two 
litres normal saline over four hours and intramuscular / intravenous  anti-emetics 
(22). All women were discharged within 24 hours and 49% within 12 hours 
(compared to 93% in the intervention group of the current study) and none of the 27 
cases were re-admitted. McCarthy et al. (2014), in an RCT comparing day-care and 
inpatient management, reported that day-care management reduced inpatient stay 
with no detrimental impact on satisfaction (23). However NVP was not objectively 
assessed in either study and women allocated to day-care management in the RCT 
were required to re-present at hospital on a daily basis to have symptoms assessed.  
The second part of the intervention was telephone support after discharge. This was 
included as many women returning to MAU with an apparent exacerbation of 
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symptoms within seven days of discharge from hospital complained of limited 
support in the community. The study research midwife attempted to telephone 
women on two occasions during the first seven days following discharge with the aim 
of  providing ongoing reassurance, encouragement, advice, identify problems, offer 
possible solutions and refer to the appropriate health care provider as necessary. 
This approach, along with a listening, sympathetic attitude, is valued by women and 
has been shown to encourage health promoting behaviours, continuance and 
adherence to advice and improve compliance with medication. (24-26). 
Unfortunately, despite pre-arranging the time, only 52% of women received both 
calls although some telephone contact was made with 81% of women. 
The PUQE score (10) was developed  from the Rhodes score, (27). This simple 
three item scoring system was highly correlated with the Rhodes score, (r=0.904), 
and has been subsequently validated (11) and used as a tool to measure severity of 
symptoms in other studies (28-32). Women scoring nine or more, the mid-point of 
the moderate category, were considered eligible to participate. It is noteworthy that 
none of the women scoring eight or less appeared clinically dehydrated which is 
similar to the finding of Lombardi and colleagues(33). They  investigated the 
effectiveness of subcutaneous metoclopramide infusions in which it was found that 
women with an initial mean (SD) PUQE score of 10 (3.0) were more likely to require 
hospital admission and IV rehydration compared to women with an initial mean (SD) 
PUQE of 7.6 (2.8).
The Medical Outcome Survey, Short Form 36, (13), was chosen as a screening tool 
to assess QoL within the study population. It is a generic measure of health status 
which has been used in a wide variety of clinical and research settings including 
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pregnancy (5, 8, 34). Results from studies involving healthy pregnant women have 
shown reduced SF36 scores in some domains, (physical function, bodily pain and 
physical limitation, (34)). These deviations can be expected when the 
psychobiological changes that occur normally during pregnancy are taken into 
consideration (35). However, results from women suffering from NVP have been 
reported to be lower than those of patients suffering from depression (8) and 
comparable with patients with chronic illness (5). The results from the current study 
are consistent with previous findings highlighting the detrimental impact of NVP not 
only on physical health but also on mental health, emotional well-being and social 
function. Whilst the eight domains of the SF36 have been validated for use in 
pregnancy it is possible that the summary scores need further testing (35). A disease 
specific QoL tool has been developed for use in women with NVP (36). It is possible 
that a more disease specific tool such as this may be more appropriate to use in 
future studies.
The short satisfaction questionnaire included six questions scored using ratings of 
agreement/disagreement on a seven point scale and was developed and validated to 
address issues theorised to affect perceptions of satisfaction with antenatal care 
(14). Satisfaction scores did not differ between groups and were comparable with 
those reported using the same questionnaire in an RCT comparing a telephone 
support intervention with routine antenatal care in low risk nulliparous women in 
which values ranged from 28-35.5 (37).
The study has several important limitations. The small number of participants and 
the low rate of completion of follow up questionnaires mean that conclusions are 
limited. Almost 40% of eligible women who presented at the MAU were either missed 
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or not approached about involvement in the trial by clinical staff. The main reason 
given for this was that staff were too busy. Further, because funding was not 
available for interpreters, non-English speaking ethnic minorities (comprising 13% of 
eligible population) were not approached, further limiting the generalisability of the 
results. Recruitment to any future trial may, therefore, benefit from greater 
engagement and involvement of the clinical staff in the design and implementation of 
the study, conducting the trial at multiple sites and employing interpretaors. The use 
of different formats for questionnaire completion and text messaging reminders may 
also help to improve questionnaire return rates. Finally, despite the likely cost 
benefits of the intervention, a formal economic evaluation was not performed. 
Conclusion
The results of this pilot RCT suggest that midwife-led outpatient care for severe NVP 
is achievable with symptomatic improvement comparable to that seen in a women 
managed as in-patients and that women are satisfied with day-case care. Further it 
provides evidence that a larger trial, with economic evaluation, is feasible and 
worthwhile in order to adequately assess whether day-case management of HG is 
cost-effective. We would recommend that such a trial focused on improvements in 
the quality of life of sufferers which gives an overall impression of wellbeing and is 
valued by women. For example, assuming a type one error rate of five percent we 
would need a sample size of 170 participants (85 in each arm) to detect an effect 
size of 0.5 standard deviations with 90% power.
Clinical Trial Registration:
ISRCTN Register, http://www.isrctn.org
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ISRCTN56847191 DOI 10.1186/ISRCTN56847191
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Table 1: Baseline characteristics of participants 
Control
(n=26)
Intervention
(n=27)
p-value
Age/years                                       27.3 (4.8) 24.5 (7.25) 0.11*
Nulliparous                                13 (50%) 17 (63%) 0.85**
White British                                    18 (69%) 22 (81%) 0.57**
Gestation at recruitment /weeks  10.3 (2.9) 9.3 (2.8) 0.35*
PUQEa score (max 15)                               11.5 (2.2) 12.6 (2.2) 0.08*
Packed Cell Volume                         0.38 (0.03) 0.38 (0.03) 0.72*
Urea (mg/dl)                                       3.2 (1.2) 3.4 (1.4) 0.55*
Ketones  3 or 4 +                      
                                                                       
13 (50%) 8 (30%) 0.13**
Weight/kg.                                  68.2 (14.1) 70.2 (16.9) 0.66*
SF36.v2 PCSb                            41.4 (10.1) 40.9 (7.8) 0.84*
SF36.v2 MCSc                           30.7 (12.5) 27.5 (13.0) 0.37*
Figures are mean (SD) or number (%)
* obtained via 2-tailed t-test
**obtained via chi-squared analysis
aPregnancy Unique Quantification of Emesis and nausea 
bShort Form36 version2 Physical component score
cShort Form 36 version2 Mental component score
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Table 2: NVP related admission and pregnancy clinical outcome measures
Control
n=26
Intervention
n=27
p- value
Number of women receiving 3 
litres IV fluid on Day 1 12 (46%) 26 (96%) 0.04**
Duration of initial attendance / 
admission  (hrs) 46.5 (24.1) 13.3 (26.8) <0.001*
Total number of all hospital 
attendances with NVP/number 
of women (% of group)           
   1
2
3
4
5
6
13 (50)
6 (23.1)
2 (7.7)
2 (7.7)
2 (7.7)
1 (3.8)
20 (74.1)
4 (14.8)
3 (11.1)
0
0
0 0.08**
Mean (SD) total admission 
time/hrs for all NVP 
attendances 94.1 (80.2) 27.2 (50.7) 0.001*
Median (IQR) total admission 
time/hrs for all NVP 
attendances
65.0 
(48.0 – 122.8)
7.0 
(6.5 – 14.0) <0.001***
Spontaneous abortions 2 (8%) 2 (7%) 1.00**
Termination of pregnancy 0 1 (4%) 1.00**
Vaginal delivery                18 (78%) 19 (79%) 1.00**
Gestation at delivery (weeks)                  38.7 (6.2) 37.4 (8.7) 0.59*
Birthweight (g).                   2918 (1040) 2847 (1230) 0.83*
SGAa infant                                  3 (14%) 3 (13%) 1.00**
SCBUb admissions             1 (5%) 2 (8%) 1.00**
Figures are mean (SD), number (%) or median (IQR) 
* obtained via 2-tailed t-test,
** obtained via Fishers exact test
*** obtained via Mann-Whitney U test
a Small for gestational age 
b Special care baby unit
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Table 3: Questionnaire outcome measures day 7 following randomisation
Control
n=18
Intervention
n=13
95% 
Confidence 
Intervals
SF36.v2 PCSa           39.1 (8.6) 42.8 (6.9) -9.71, 2.48
SF36.v2 MCSb          35.1 (12.5) 34.0 (9.8) -7.62, 9.91
PUQEc                       6.2 (2.3) 6.9 (4.1) -3.07, 1.67
PUQE day 1-7 Area 
under curve**                          49.8 (13.8) 55.7 (18.4) -17.74, 5.91
Satisfaction Score*** 29.8 (4.7) 29.2 (3.3) -2.63, 3.89
Figures are mean (SD) 
* obtained via 2-tailed t-test]
** Based on 18 responses in the control group and 13 responses in the intervention group
*** Based on 17 responses in the control group and 12 in the intervention group. 
aShort Form36 version2 Physical component score
bShort Form 36 version2 Mental component score
cPregnancy Unique Quantification of Emesis and Nausea score
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Figure 1 CONSORT diagram
Ineligible women
n=58
Reasons:-
19 = Did not warrant treatment
8 = Medical condition
21 = Required interpreter
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attending
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Eligible women
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n=23
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approached 
n=50
Control    
Group
n=26
Intervention 
group
n=27
Questionnaire 
2 returned 
n=18 (69%)
Questionnaire 
2 returned 
n=12 (44%)
